

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Hashime KANAZAWA et al. : **Mail Stop: PCT**
Serial No. NEW : Attorney Docket No. 2006_1265A
Filed August 8, 2006 :

COMBINED PHARMACEUTICAL
COMPOSITION
[Corresponding to PCT/JP05/001801
Filed February 8, 2005]

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEES FOR THIS PAPER TO DEPOSIT
ACCOUNT NO. 23-0975

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

- each U.S. Patent and U.S. Patent application publication;
- each reference previously cited in the international application PCT/_____; and/or
- each reference previously cited in prior parent application Serial No. _____.
- 1a. This Information Disclosure Statement is submitted:
within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or
before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

- 1b. This Information Disclosure Statement is submitted after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:
- (1) the certification of paragraph 2 below is provided, **or**
(2) the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.
- 1c. This Information Disclosure Statement is submitted: after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:
the certification of paragraph 2 below is provided, and
the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.
2. It is hereby certified
- a. that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or
- b. that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.
3. Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.

4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
 - a. [X] a full or partial English language translation submitted herewith,
 - b. [X] the International Search Report (in the English language) submitted herewith,
 - c. [X] the concise explanation contained in the specification of the present application at pages 2-5,
 - d. [X] the concise explanation set forth in the attached English language abstract,
 - e. [] the concise explanation set forth below or on a separate sheet attached to the reference:
5. [] A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Hashime KANAZAWA et al.

By _____

Warren M. Cheek Jr.
Warren M. Cheek Jr.
Registration No. 33,367
Attorney for Applicants

WMC/jmj
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
August 8, 2006

Sheet 1 of 2

INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)

U. S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: August 8, 2006

ATTY DOCKET NO.
2006_1265ASERIAL NO.
NEW 10/588725APPLICANT
Hashime KANAZAWA et al.FILING DATE
August 8, 2006

GROUP

U. S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/J.L./	AA	6,372,790	4/2002	Bonhomme et al.			corres to AB

FOREIGN PATENT DOCUMENTS

/J.L./		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AB	2002-502869	1/2002	JP			
	AC	99/40904	8/1999	WO			corres to AB
	AD	03/082283	10/2003	WO			
	AE	64-071813	3/1989	JP			Abstract
	AF	2002-533410	10/2002	JP			
	AG	00/38724	7/2000	WO			corres to AF
	AH	2002-533413	10/2002	JP			
	AI	00/38727	7/2000	WO			corres to AH
	AJ	2003-528928	9/2003	JP			
	AK	01/74394	11/2001	WO			corres to AJ
	AL	2001-294537	10/2001	JP			Full
↓	AM	2001-514224	9/2001	JP			
/J.L./	AN	99/11263	11/1999	WO			corres to AM

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

/J.L./	AO	Alawi A.A., Heather M.A., Richard H.K., Risk of adverse events with concomitant use of atorvastatin or simvastatin and glucose-lowering drugs (thiazolidinediones, metformin, sulfonylurea, insulin, and acarbose), The American Journal of Cardiology, 2002, Vol.89, pgs. 1308-1310, table 1, pg. 1309, left column, lines 1 to 6.
/J.L./	AP	Edited by Chikako TANAKA, Ryuichi KATO "NEW Yakurigaku (revised 3 rd edition)", Nankodo Co., Ltd., 25 November, 1996 (25.11.96), pages 403 to 405, 504 to 506, full text.
/J.L./	AQ	Tener D., Serkan T., Zeynep O., Hasan I., Fenofibrate treatment is associated with better glycemic control and lower serum leptin and insulin levels in type 2 diabetic patients with hypertriglyceridemia, European Journal of Internal Medicine, 2003, Vol.14, pages 357 to 360, full text, particularly, page 359, table 2.

EXAMINER /Jonathan Lau/ DATE CONSIDERED 12/13/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 2 of 2

INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: August 8, 2006

ATTY DOCKET NO.
2006_1265ASERIAL NO.
NEW
10/588725APPLICANT
Hashime KANAZAWA et al.FILING DATE
August 8, 2006

GROUP

U. S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						
	BE						
	BC						
	BD						
	BE						
	BE						
	BC						
	BH						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
/J.L./	BI	07-053409	2/1995	JP			Full
/J.L./	BJ	2780932	5/1998	JP			corres to BI
/J.L./	BA	09-067271	3/1997	JP			Full
/J.L./	BE	3148973	7/2001	JP			corres to BK
/J.L./	BM	01-47468	7/2001	WO			Abstract
/J.L./	BN	2001-316293	11/2001	JP			Full

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

/J.L./	BO	Akira OSAWA, "Koshi Kessho Chiryozai Bezafibrate no Chutodo ni Control sareta NIDDM ni okeru Ketto Koka Sayo", The Journal of the Japan Diabetic Society, 1994, Vol.37, No.1, pages 17 to 22, page 18, tables 1, 2, page 19, table 4.
	BP	
	BQ	

EXAMINER /Jonathan Lau/

DATE CONSIDERED

12/13/2007